The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
Hepatobiliary Surg Nutr
.
2023 Feb 28;12(1):148-150.
doi: 10.21037/hbsn-22-280.
Epub 2023 Jan 16.
Authors
Sabine Lieb
1
,
Sebastian Ebel
2
,
Daniel Seehofer
3
,
Thomas Berg
1
,
Florian van Bömmel
1
Affiliations
1
Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
2
Department of Diagnostic and Interventional Radiology, Leipzig University Medical Center, Leipzig, Germany.
3
Department of Visceral, Vascular, Thoracic and Transplant Surgery, Leipzig University Medical Center, Leipzig, Germany.
PMID:
36860264
PMCID:
PMC9944522
DOI:
10.21037/hbsn-22-280
No abstract available
Publication types
Comment